Pfizer Corporation

Other

Michael Eric Green

Michael Aaron Brodney

Lei Zhang

David Lawrence Firman Gray

Bruce Nelsen Rogers

Chakrapani Subramanyam

Scot Richard Mente

Jennifer Elizabeth Davoren

Ivan Viktorovich Efremov

Steven Victor O'Neil

Amy Beth Dounay

Jaclyn Louise Henderson

Chewah Lee

Christopher John O'Donnell

Martin Youngjin Pettersson

Douglas Scott Johnson

Christopher William Am Ende

Tuan Phong Tran

Cory Michael Stiff

Patrick Robert Verhoest

Gregory Wayne Kauffman

Christopher John O'donnell

Haiyin He

Nandini Chaturbhai Patel

Antonia Friederike Stepan

Hui Yu Yang

Sujiet Puthenveetil

Kenneth John Dirico

Alessandra S Eustaquio

Anokha Ratnayake

Jesse Alexander Teske

Frank Erich Koehn

Min He

Thayalan Navaratnam

Patrick Bradley Mullins

Benjamin Adam Fish

Justin Ian Montgomery

Kapildev Kashmirilal Arora

Natasha Mariam Kablaoui

Danica Antonia Rankic

Matthew Francis Dunn

Anokha Sayani Ratnayake

David Lawrence Gray

Steven Victor O'neil

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

Heteroaromatic compounds and their use as dopamine D1 ligands

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (&#x3ba;-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.

Heteroarylphenoxy benzamide kappa opioid ligands

A Pre-Rolled Smoking Paper Stuffer has a chimney which includes a separator wall bin, converging guide, cradle, tip spacer, and base walls and an extractor base which includes an extractor block, alignment block, and tip pusher. A smoking paper can be inserted into the cradle. Smoking materials are placed into the bin and flow out of the bin and into the converging guide which funnels them into the smoking paper held within the cradle. Once filled, the chimney is pressed onto the base and the alignment block aligns the tip pusher with the smoking-end of the paper. As the chimney continues to be pushed down, the tip pusher displaces the filled smoking paper up and out of the top of the cradle. The stuffed paper can be grasped and lifted out of the stuffer. Multiple stuffers can be attached to one another via the use of various attachment means.

Pre-rolled smoking paper stuffer

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

Spliceostatin analogs and methods for their preparation

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders

The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression. 

Heterocyclic compounds and their use as dopamine D1 ligands

Substituted 1,7-naphthyridines as dopamine D1 ligands

Growing community of inventors

Boston, MA, United States of America

Michael Eric Green